LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it met its target of 630 patients for the SYMMETRYSM trial - a global, pivotal Phase 3 clinical trial to evaluate the efficacy and safety of elesclomol in patients with stage IV metastatic melanoma.
